ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Julie Vose Was Elected President of the American Society of Clinical Oncology

January 3, 2014

FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer

July 27, 2012

NCI Cooperative Group Clinical Trials Approved

September 24, 2010

Reauthorization Bill Ready For Senate Floor; Report to Panel Makes Clear Why Renewal Needed

April 22, 1988

DCE Board Approves Recompetition Of Two Major Contracts

October 30, 1987

NCAB Sets Bypass Budget Figures at $1.074 Billion

May 28, 1982